Literature DB >> 35120057

Discordance Between Self-reported and Biologically Tested Exposure to Fentanyl Among People at Risk of Opioid Overdose.

Ju Nyeong Park1, Glenna Urquhart, Miles Morris, Rejwi Dahal, Saba Rouhani, Susan G Sherman.   

Abstract

Drug overdose remains a leading cause of death in the US, and the majority of opioid overdose fatalities involve fentanyl. This study aims to measure the degree of concordance between self-reported and biologically tested exposure to fentanyl. We conducted a cross-sectional analysis using survey and urinalysis data collected between 2019 and 2020 from Anne Arundel County, Maryland. Among urinalysis participants (n = 113), 30% reported daily fentanyl use, and among this group, only 54% had a fentanyl-positive result. Cohen Kappa between self-reported and biologically detected fentanyl use was 0.26, indicating minimal agreement between the 2 markers. Limitations to interpreting self-reported and urinalysis data are discussed in this report.
Copyright © 2022 American Society of Addiction Medicine.

Entities:  

Year:  2022        PMID: 35120057      PMCID: PMC9349466          DOI: 10.1097/ADM.0000000000000969

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   4.647


  10 in total

1.  Evaluation of fentanyl test strip distribution in two Mid-Atlantic syringe services programs.

Authors:  Ju Nyeong Park; Sari Frankel; Miles Morris; Olivia Dieni; Lynn Fahey-Morrison; Martin Luta; Derrick Hunt; Jeffery Long; Susan G Sherman
Journal:  Int J Drug Policy       Date:  2021-03-10

2.  The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States.

Authors:  Brooke Hoots; Alana Vivolo-Kantor; Puja Seth
Journal:  Addiction       Date:  2020-01-07       Impact factor: 6.526

3.  Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence.

Authors:  Susan G Sherman; Kenneth B Morales; Ju Nyeong Park; Michelle McKenzie; Brandon D L Marshall; Traci Craig Green
Journal:  Int J Drug Policy       Date:  2019-04-13

4.  Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework.

Authors:  Ju Nyeong Park; Saba Rouhani; Leo Beletsky; Louise Vincent; Brendan Saloner; Susan G Sherman
Journal:  Milbank Q       Date:  2020-08-18       Impact factor: 4.911

5.  An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples.

Authors:  Traci C Green; Ju Nyeong Park; Michael Gilbert; Michelle McKenzie; Eric Struth; Rachel Lucas; William Clarke; Susan G Sherman
Journal:  Int J Drug Policy       Date:  2020-01-14

6.  Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence.

Authors:  Saba Rouhani; Ju Nyeong Park; Kenneth B Morales; Traci C Green; Susan G Sherman
Journal:  Harm Reduct J       Date:  2019-06-24

7.  Polysubstance Overdose Deaths in the Fentanyl Era: A Latent Class Analysis.

Authors:  Ju Nyeong Park; Kristin E Schneider; David Fowler; Susan G Sherman; Ramin Mojtabai; Paul S Nestadt
Journal:  J Addict Med       Date:  2022 Jan-Feb 01       Impact factor: 3.702

8.  Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States.

Authors:  Nicholas C Peiper; Sarah Duhart Clarke; Louise B Vincent; Dan Ciccarone; Alex H Kral; Jon E Zibbell
Journal:  Int J Drug Policy       Date:  2018-10-03

9.  Interrater reliability: the kappa statistic.

Authors:  Mary L McHugh
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

10.  Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada.

Authors:  Ashraf Amlani; Geoff McKee; Noren Khamis; Geetha Raghukumar; Erica Tsang; Jane A Buxton
Journal:  Harm Reduct J       Date:  2015-11-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.